您的位置: 首页 > 2019年5月 第50卷 第3期 > 文字全文
2023年7月 第38卷 第7期11
目录

定向斑块旋切系统联合药物涂层球囊在下肢动脉硬化闭塞症中的临床应用

Clinical application of Turbohawk atherectomy device combined with drug-coated balloon in treatment of arteriosclerosis obliterans in lower extremity

来源期刊: 广州医药 | 27-29 发布时间:2021-12-17 收稿时间:2025/11/13 17:27:53 阅读量:13
作者:
关键词:
定向斑块旋切系统药物涂层球囊下肢动脉硬化闭塞症
Turbohawk atherectomy deviceDrug-coated balloonArteriosclerosis obliterans in lower extremity
DOI:
10.3969/j.issn.1000-8535.2019.03.007
收稿时间:
2019-01-24 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 评价Turbohawk定向斑块切除系统联合药物涂层球囊在下肢动脉硬化闭塞症中临床应用价值。方法 对于术前超声以及下肢动脉CTA检查诊断为下肢动脉硬化闭塞症的8例患者,行Turbohawk斑块旋切以及药物涂层球囊治疗,术后行常规抗凝治疗,定期行彩超复查。结果 8例患者下肢动脉均全部再通成功,技术成功率为100%,术后缺血症状明显改善,术后平均踝肱指数为0.78±0.06,高于术前的0.31±0.12(P<0.05)。住院期间无并发症发生,随访3~18个月,患者保肢均获得成功。结论 Turbohawk定向机械旋切系统联合药物涂层球囊治疗下肢动脉硬化闭塞症,具有创伤小、疗效好以及安全性高等优点,值得临床推广使用。
Objective To evaluate clinical application of using Turbohawk atherectomy device in combination with drug-coated balloon in treatment of atreriosclerosis obliterans in lower extremity. Methods Turbohawk atherectomy device and DCB was performed in 8 patiments with atreriosclerosis obliterans in lower extremity. All patients were diagnosed by ultrasound and CTA. Routine anticoagulation drugs were used after the operation. Follow-up was carried out with color Doppler ultrasound. Results Revascularization was gained in 8 patients. The technically successful rate was 100% and ischemic symptoms relieved significantly immediately after the operation. The post-operative ankle brachinal index(ABI) was 0.78±0.06,which was higher than that of before operation(0.31±0.12). No obvious complications occurred after operation. The follow-up range was 3~18 months and limbs were salvaged successfully. Conclusion With minimal invasive, safe and few complications, Turbohawk atherectomy device in combination with drug-coated balloon is proved to be a very effective treatment atreriosclerosis obliterans in lower extremity and it is worth to popularize.
1、 JIA X, ZHANG J, ZHUANG B, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the Aco Art I Trial [J]. JACC Cardiovasc Interv, 2016, 9(18): 1941-1949. JIA X, ZHANG J, ZHUANG B, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the Aco Art I Trial [J]. JACC Cardiovasc Interv, 2016, 9(18): 1941-1949.
2、 孙灿龙,杜建时,韩冬梅.药物涂层球囊对老年患者下肢动脉硬化闭塞症支架内狭窄的疗效 [J]. 中国老年学杂志,2017,37(11): 5375-5377. 孙灿龙,杜建时,韩冬梅.药物涂层球囊对老年患者下肢动脉硬化闭塞症支架内狭窄的疗效 [J]. 中国老年学杂志,2017,37(11): 5375-5377.
3、 ROBERTS D, NIAZI K, MILLER W, et al. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the definitive Ca trial [J]. Catheter Cardiovasc Interv, 2014, 84(2): 236-244. ROBERTS D, NIAZI K, MILLER W, et al. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the definitive Ca trial [J]. Catheter Cardiovasc Interv, 2014, 84(2): 236-244.
4、 MC KINSEY J F, ZELLER T, ROCHA-SINGH K J, et al. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the definitive le study [J]. JACC Cardiovasc Interv, 2014, 7(8): 923-933. MC KINSEY J F, ZELLER T, ROCHA-SINGH K J, et al. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the definitive le study [J]. JACC Cardiovasc Interv, 2014, 7(8): 923-933.
5、 POWELL R J. Endovascular treatment in the superficial femoral artery: which devices, where? [J]. Semin Vasc Surg, 2008,21(4): 180-185. POWELL R J. Endovascular treatment in the superficial femoral artery: which devices, where? [J]. Semin Vasc Surg, 2008,21(4): 180-185.
6、 SIMPSON J B. How atherectomy began: a personal history [J]. Am J Cardiol, 1993,72(13): 3E-5E. SIMPSON J B. How atherectomy began: a personal history [J]. Am J Cardiol, 1993,72(13): 3E-5E.
7、 SOGA Y, TOMOI Y, SATO K, et al. Clinical outcome after endovascular treatment for isolated common femoral and popliteal artery disease [J]. Cardiovasc Interv Ther, 2013, 28(3): 250-257. SOGA Y, TOMOI Y, SATO K, et al. Clinical outcome after endovascular treatment for isolated common femoral and popliteal artery disease [J]. Cardiovasc Interv Ther, 2013, 28(3): 250-257.
8、 ROCHA-SINGH K J, JAFF M R, CRABTREE T R, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease [J]. Catheter Cardiovasc Interv, 2007, 69(6): 910-919. ROCHA-SINGH K J, JAFF M R, CRABTREE T R, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease [J]. Catheter Cardiovasc Interv, 2007, 69(6): 910-919.
9、 师贞爱,刘育齐,何子聪,等. Turbohawk斑块旋切及Rotarex除栓导管治疗下肢动脉硬化闭塞症的现状 [J]. 中国血管外科杂志,2017,9(4): 306-310. 师贞爱,刘育齐,何子聪,等. Turbohawk斑块旋切及Rotarex除栓导管治疗下肢动脉硬化闭塞症的现状 [J]. 中国血管外科杂志,2017,9(4): 306-310.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录